Lp-PLA2 Activity

Introduction

As a nurse practitioner with an autonomous practice in Florida, I’ve had the opportunity to delve into various biomarkers that serve as critical indicators of cardiovascular health. One such biomarker is Lipoprotein-associated phospholipase-A2 (Lp-PLA2) activity. This enzyme, produced by a variety of cells, plays a pivotal role in cardiovascular health, and understanding its activity can provide significant insights into a patient’s risk for cardiovascular disease (CVD). In this article, we’ll explore the background, clinical implications, ranges, and factors affecting Lp-PLA2 activity.

Background on Lp-PLA2 Activity

Lp-PLA2 is an enzyme that becomes active in the presence of oxidized lipoproteins. Its primary function is to hydrolyze oxidized phospholipids, which are components of low-density lipoprotein (LDL) particles. Elevated levels of Lp-PLA2 activity have been associated with an increased risk of cardiovascular events, such as myocardial infarction (MI), coronary revascularization, and coronary heart disease (CHD)–related death. Measuring the activity of Lp-PLA2 in nmol/min/mL is considered more accurate than measuring its concentration in ng/mL, as the activity measurement is less prone to variability and unaffected by the presence of inactive enzymes.

Clinical Implications of Lp-PLA2 Activity

Low Lp-PLA2 Activity

A low or optimal level of Lp-PLA2 activity indicates a reduced risk of cardiovascular disease and stroke. It suggests lower vascular inflammation, which is a critical factor in the development of atherosclerosis. Clinical studies have shown that individuals with low Lp-PLA2 activity have a decreased risk of developing cardiovascular events over time.

Lifestyle Factors for Low Lp-PLA2 Activity:

• Dietary Adjustments: Replacing 5% of dietary energy from carbohydrates with energy from protein and following a vegetarian diet have been associated with lower Lp-PLA2 activity.
  
• Moderate Alcohol Consumption: Moderate intake of alcohol has been linked to reduced enzyme activity.
  
• Body Mass Index (BMI): Maintaining a BMI of ≤ 25.
  
• Postmenopausal Hormone Use: Associated with reduced Lp-PLA2 activity.
  
• Non-smoking Status: Non-smokers generally exhibit lower enzyme activity.

   

High Lp-PLA2 Activity

Increased Lp-PLA2 activity is a significant marker for heightened risk of coronary heart disease and related events. Clinical evidence suggests that elevated Lp-PLA2 activity doubles the likelihood of a cardiac event within five years. This heightened risk underscores the importance of monitoring and managing Lp-PLA2 activity levels.

Lifestyle Factors for High Lp-PLA2 Activity:

• Smoking: Smoking is strongly associated with increased enzyme activity.
  
• Obesity: Higher BMI, increased waist circumference, and body fat percentage correlate with elevated Lp-PLA2 activity.
  
• Aspirin Use: Although commonly used for heart health, aspirin can increase Lp-PLA2 activity.
  
• Hypercholesterolemia: High cholesterol levels are linked to increased enzyme activity.
  
• Age: Older age is a contributing factor to higher Lp-PLA2 activity.

   

Ranges and Measurements

The standard range for Lp-PLA2 activity is 0.00–123.00 nmol/min/mL, with an optimal range of 0.00–75.00 nmol/min/mL. These values are critical for healthcare providers to assess cardiovascular risk and implement appropriate interventions. The measurement of Lp-PLA2 activity provides a more stable and reliable indicator of active oxidation than concentration measurements.

Interfering Factors and Drug Associations

Several factors can interfere with the measurement and interpretation of Lp-PLA2 activity:

• Lifestyle Factors: Diet, weight, smoking status, and alcohol consumption can significantly impact enzyme activity.
  
• Medications: Certain medications can influence Lp-PLA2 levels. For instance, darapladib was studied for its potential to reduce Lp-PLA2 activity, but it did not demonstrate a reduction in coronary events.
  
• Inflammatory Conditions: Conditions that increase systemic inflammation can also elevate Lp-PLA2 activity.

   

Reducing Lp-PLA2 Activity

Reducing Lp-PLA2 activity is essential for lowering cardiovascular risk. Lifestyle modifications—such as adopting a heart-healthy diet rich in omega-3 fatty acids—can naturally reduce enzyme activity. Regular physical activity, maintaining a healthy weight, and avoiding smoking are also effective strategies. While certain medications have been explored for their potential to lower Lp-PLA2 activity, lifestyle changes remain the most effective and sustainable approach.

In conclusion, a comprehensive evaluation by a functional medicine nurse practitioner in Florida facilitates identification of cellular-level and molecular imbalances driving cardiovascular inflammation. By integrating evidence-based therapies with peptide therapy services—where vascular health is often impacted—we offer patients a regenerative, preventive framework to rebuild resilience and optimize wellness. Call (904) 799-2531 or schedule online to request your personalized cardiovascular health assessment.

Further Reading

• Pirro, M., et al. (2015). Lipoprotein-associated phospholipase A2 prognostic role in cardiovascular disease: A review of experimental and clinical studies. International Journal of Molecular Sciences, 16(10), 24554–24573. https://pmc.ncbi.nlm.nih.gov/articles/PMC4620072/

• Packard, C. J., et al. (2013). Changes in lipoprotein-associated phospholipase A2 activity predict coronary heart disease events: Results from the LIPID study. Journal of the American Heart Association, 2(6), e000360. https://www.ahajournals.org/doi/pdf/10.1161/JAHA.113.000360

• He, Y., et al. (2014). Evaluation of lipoprotein-associated phospholipase A2 in healthy Chinese Han adults: Establishment of reference intervals. Clinical Biochemistry, 47(15), 1380-1384. https://pmc.ncbi.nlm.nih.gov/articles/PMC3895822/

• Bittner, V. (2020). PLAC test for Lp-PLA2 activity to predict coronary heart disease: Clinical utility and limitations. American Family Physician, 101(1), 44-50. https://www.aafp.org/pubs/afp/issues/2020/0101/p44.html